# US 2021/0196795 A1 · Therapeutic use of vegf-c and ccbe1

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0196795 A1
- Document ID: US20210196795A1
- Status: Published application
- Kind: A1
- Application number: 17/247,441
- Filed: 2020-12-11
- Published: 2021-07-01
- Earliest claimed: 2013-08-14
- Assignees: Laurantis Pharma Oy
- Applicants: Laurantis Pharma Oy
- Inventors: Kari ALITALO; Michael JELTSCH; Andrey ANISIMOV
- Web page: https://patentgrep.com/patent/US20210196795A1

## CPC

- A61K 38/1866: {Vascular endothelial growth factor [VEGF]}
- A61K 38/1709: {from mammals}
- A61K 38/1738: {Calcium binding proteins, e.g. calmodulin}
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61P 7/10: Antioedematous agents; Diuretics
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C07K 2319/036: targeting to the medium outside of the cell, e.g. type III secretion
- C12N 15/85: for animal cells
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to therapeutic methods, uses and compositions comprising CCBE1 and VEGF-C for treating disorders and conditions involving impaired lymphatic system, particularly lymphedema.

## Claims

### Claim 1

A method of treating lymphedema by administering to a patient in need thereof:
I) a first component comprising at least one of the group consisting of:
a) full-length CCBE1,
b) a fragment of CCBE1 having the ability to cleave full-length VEGF-C,
c) an amino acid sequence having at least 80% identity to full-length CCBE1 or to said fragment of CCBE1, wherein said amino acid sequence has the ability to cleave full-length VEGF-C, and
d) a polynucleotide encoding any of a) through c) above; and
II) a second component comprising at least one of the group consisting of:
e) VEGF-C,
f) a fragment of VEGF-C having the ability to bind to and activate VEGFR-2 and/or VEGFR-3,
g) an amino acid sequence having at least 80% identity to full-length VEGF-C or to said fragment of VEGF-C, wherein said amino acid sequence has the ability to bind to and activate, VEGFR-2 and/or VEGFR-3, and
h) a polynucleotide encoding any of e) through g) above;
wherein said first and second components are administered simultaneously, separately or sequentially.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the CCBE1 is administered in the form of a polypeptide comprising amino acids 35-406 set forth in SEQ ID NO: 1, or an amino acid sequence having at least 80% amino acid sequence identity therewith.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the CCBE1 is administered via a polynucleotide comprising a nucleic acid sequence set forth in SEQ ID NO: 2 or a nucleic acid sequence having at least 80% nucleic acid sequence identity therewith.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the VEGF-C is administered in the form of a polypeptide comprising an amino acid sequence selected from the group consisting of amino acids 32-419 of SEQ ID NO: 3; amino acids 32-227 covalently linked to amino acids 228-419 of SEQ ID NO: 3; amino acids 112-227 of SEQ ID NO: 3; amino acids 103-227 of SEQ ID NO: 3; and an amino acid sequence having at least 80% amino acid sequence identity therewith.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the VEGF-C is administered in the form of a polynucleotide comprising a nucleic acid sequence selected from the group consisting of nucleic acids 524-1687 of SEQ ID NO: 4; nucleic acids 737-1687 of SEQ ID NO: 4; nucleic acids 764-1687 of SEQ ID NO: 4; nucleic acids 737-1111 of SEQ ID NO: 4; nucleic acids 764-1111 of SEQ ID NO: 4; and a nucleic acid sequence having at least 80% nucleic acid sequence identity therewith.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the lymphedema is selected from the group consisting of primary lymphedema, Milroy's syndrome, Meige's lymphedema, lymphedema tarda, secondary lymphedema, and lipedema.

### Claim 7 (depends on 1)

The method according to claim 1, comprising the DNA comprising a sequence having at least 80% identity to the sequence of SEQ ID NO: 2.

### Claim 8 (depends on 1)

The method according to claim 1, comprising a DNA comprising a sequence having at least 80% identity to the sequence of SEQ ID NO: 4.

### Claim 9 (depends on 1)

The method according to claim 1, comprising a DNA comprising a sequence having at least 95% identity to the sequence of SEQ ID NO: 2 and a DNA comprising a sequence having at least 95% identity to the sequence of SEQ ID NO: 4.

### Claim 10 (depends on 1)

The method according to claim 1, comprising the DNA comprising the sequence of SEQ ID NO: 2 and the DNA comprising the sequence of SEQ ID NO: 4.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the composition is capable of promoting growth and/or survival of Ba/F3-VEGFR-3/EpoR cells.

### Claim 12 (depends on 1)

The method, according to claim 1, wherein the first and/or second component administered in a pharmaceutically acceptable vehicle.

### Claim 13 (depends on 1)

The method according to claim 1, wherein the CCBE1 enhances proteolytic processing.

### Claim 14 (depends on 1)

The method according to claim 1, wherein the VEGF-C is full-length VEGF-C, prepro-VEGF-C, partially processed VEGF-C or fully processed mature VEGF-C.

### Claim 15 (depends on 1)

The method of claim 1, wherein the administration is achieved by gene therapy, protein therapy, or any combination thereof.

### Claim 16 (depends on 1)

The method of claim 1, wherein the patient has an impaired lymphatic system.

### Claim 17 (depends on 15)

The method of claim 15, wherein viral vectors are used.

### Claim 18 (depends on 17)

The method of claim 17, wherein the viral vectors are selected from the group consisting of lentivirus vectors, adeno-associated viral vectors and adenoviral vectors.

### Claim 19 (depends on 15)

The method of claim 15, wherein naked DNA is used.

### Claim 20 (depends on 19)

The method of claim 19, wherein the vector is administered, optionally in a pharmaceutically acceptable carrier, in an amount of 107 to 1013 viral particles, preferably in an amount of at least 109 viral particles.

### Claim 21 (depends on 20)

The method of claim 20, wherein protein therapy is employed.

### Claim 22 (depends on 21)

The method of claim 21, wherein the dose is in the range of 0.01 to 20 mg/kg, more preferably in the range of 0.1 to 10 mg/kg, most preferably 0.5 to 5 mg/kg.

### Claim 23 (depends on 21)

The method of claim 21, wherein the dosage is administered in one or more doses at suitable intervals.

### Claim 24 (depends on 21)

The method of claim 21, wherein a daily dose is from about 50 mg/day to about 300 mg/day.

### Claim 25 (depends on 1)

The method of claim 1 for use in prophylaxis, amelioration, or alleviation of disorders or symptoms related to impaired lymphatic system.

### Claim 26 (depends on 1)

The method of claim 1, wherein the components are administered via parenteral delivery, enteral delivery, local administration or topical administration.
